Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Development programme

GLORY — mazdutide

The phase 3 weight-management programme for the GLP-1 and glucagon receptor dual agonist mazdutide, conducted principally in China.

Sponsor class: Manufacturer-sponsored. First record: 2022.

Filter by text

Phase

Status

Showing 0 records on this page

Records in this programme

5 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

Record	Compound	Phase	Status	Design	Randomised	Year	Certainty
GLORY-1	Mazdutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	610	2025	Moderate
GLORY-1-OLEprogramme record	Mazdutide	Phase 3	Reported	Single-arm open-label	—	2025	Very low
GLORY-1-QOLprogramme record	Mazdutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2025	Very low
GLORY-1-REGIONAL-CNprogramme record	Mazdutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2025	Very low
GLORY-1-REGIONAL-JPprogramme record	Mazdutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2025	Very low

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.